Novo Nordisk A/S share price logo

Novo Nordisk A/S

NYSE: NVO

Mega Cap

$46.91

-0.09

(-0.19%)

Live

as on

Novo Nordisk A/S Stock Performance

as on May 14, 2026 at 4:08 am IST

  • Day's Low

    Day's High

    $46.65
    $47.21
    downward going graph

    0.55%

    Downside

    0.64%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $35.12
    $81.44
    downward going graph

    25.13%

    Downside

    73.61%

    Upside

    downward going graph

Novo Nordisk A/S share price movements today

Previous Close
$47.00
Open
$46.96
Volume
6.2M
Day's Low - High
$46.65 - $47.21
52 Week Low - High
$35.12 - $81.44

Novo Nordisk A/S Historical Returns

1 Month Return
+ 23.75 %
3 Month Return
-5.18 %
1 Year Return
-28.13 %
3 Year Return
-45.12 %
5 Year Return
+ 19.15 %

Novo Nordisk A/S Stock Fundamentals & Key Indicators

Check Novo Nordisk A/S market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$205.7B

EPS (TTM)

23.3746

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.67%

PE Ratio (TTM)

10.79

Industry PE ratio

21.26875

PEG Ratio

3.3679

EBITDA

173.9B

Revenue (TTM)

327.8B

Profit Margin

37.21%

Return On Equity TTM

71.40%

Novo Nordisk A/S Stock Valuation

Track how Novo Nordisk A/S P/E has moved over time to understand its valuation trends.

Novo Nordisk A/S in the last 5 years

  • Overview

  • Trends

Lowest (2.05x)

March 31, 2026

Today (10.79x)

May 13, 2026

Industry (21.27x)

May 13, 2026

Highest (45.23x)

June 30, 2024

LowHigh

Today’s Price to Earnings Ratio: 10.79x

Novo Nordisk A/S vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Novo Nordisk A/S with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Novo Nordisk A/S image
Novo Nordisk A/S
BUY$205.7B19.15%10.7937.21%
AstraZeneca PLC image
AstraZeneca PLC
BUY$282.0B235.22%27.3917.19%
Eli Lilly and Company image
Eli Lilly and Company
BUY$862.3B407.78%34.3334.99%
AbbVie Inc image
AbbVie Inc
BUY$358.3B78.27%99.45.79%
Johnson & Johnson image
Johnson & Johnson
BUY$533.0B31.95%25.6321.83%
See all

Stock Returns calculator for Novo Nordisk A/S Stock including INR - Dollar returns

The Novo Nordisk A/S stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Novo Nordisk A/S investment value today

Current value as on today

₹80,501

Returns

-₹19,499

(-19.5%)

Returns from Novo Nordisk A/S Stock

-₹28,272 (-28.27%)

Dollar Impact

₹8,774 (+8.77%)

Analyst Recommendation on Novo Nordisk A/S Stock

Based on 32 analysts

BUY

62.50%

Buy

31.25%

Hold

6.25%

Sell

Based on 32 analysts, 62.5% of analysts recommend a 'BUY' rating for Novo Nordisk A/S. Average target price of $47.14

Novo Nordisk A/S Share Price Target

Get share price movements and forecasts by analysts on Novo Nordisk A/S.

What analysts predicted

0.49%UPSIDE

Target Price

$47.14

Current Price

$46.91

Analyzed by

32 Analysts

Target

$47.14

Novo Nordisk A/S target price $47.14, a slight upside of 0.49% compared to current price of $46.91. According to 32 analysts rating.

Indian Investors' Interest in Novo Nordisk A/S Stock

Investment in Novo Nordisk A/S Shares on INDmoney has dropped by -9.68% in the last 30 days, indicating reduced investment activity.

Time period: to

Change:-9.68% versus previous 30 day period

Search interest for Novo Nordisk A/S Stock has increased by 45% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:45% versus previous 30 day period

Novo Nordisk A/S Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
9,645
9,525
9,818
10,615
12,018
11,320
76,857
74,976
79,144
96,823
Gross Profit
8,179
8,080
8,336
8,931
10,192
9,451
64,011
57,072
63,996
83,225
Operating Income
26,766
31,846
25,934
33,822
36,737
38,791
33,449
23,682
31,736
59,618
EBITDA
28,511
36,906
35,739
37,355
45,848
46,046
43,596
31,439
37,298
69,207
Interest Expense
916
2,074
1,562
821
5,093
5,183
4,958
5,007
8,630
3,499
Depreciation
2,992
2,914
8,845
2,150
5,198
3,830
4,833
7,757
5,562
3,536
Income Before Tax
27,620
31,918
25,332
34,384
35,557
37,033
33,805
25,517
34,185
62,172
Income Tax Expense
5,657
6,511
5,282
7,083
7,327
7,999
7,302
5,511
7,294
13,615
Net Income
3,216
3,703
2,892
4,063
3,959
4,209
26,503
20,006
26,891
48,557
Net Profit Margin
33.35%
38.88%
29.46%
38.28%
32.95%
37.18%
34.48%
26.68%
33.98%
50.15%

Novo Nordisk A/S Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
15,844
17,755
17,040
18,147
20,749
21,403
25,173
34,014
40,735
309,064
Gross Profit
13,408
14,952
14,356
15,159
17,328
17,807
21,126
28,776
34,490
250,276
Operating Income
48,432
48,967
47,248
52,483
54,126
58,644
74,809
102,574
128,339
127,658
EBITDA
51,056
51,952
51,625
54,434
59,273
65,394
76,802
114,629
147,938
156,729
Interest Expense
65
90
85
220
390
289
378
542
1,640
4,207
Depreciation
-
3,182
3,925
5,661
5,753
6,025
7,362
9,413
19,107
21,982
Income Before Tax
47,798
48,680
47,615
48,553
53,130
59,080
69,062
104,674
127,191
130,540
Income Tax Expense
9,873
10,550
8,987
9,602
10,992
11,323
13,537
20,991
26,203
28,106
Net Income
5,375
6,061
5,886
5,792
6,887
7,259
7,898
12,255
14,165
102,434
Net Profit Margin
33.93%
34.14%
34.54%
31.92%
33.19%
33.92%
31.38%
36.03%
34.78%
33.14%

Novo Nordisk A/S Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
25,407
20,050
27,301
28,230
29,034
26,503
20,006
26,891
48,557
Operating Cash Flow
14,314
50,503
43,850
12,301
24,591
40,785
46,107
7,619
24,084
Investing Cash Flow
3,956
-20,731
-20,904
-91,216
-6,673
-14,248
-15,425
-42,812
-11,712
Financing Cash Flow
-26,382
16,683
-18,401
36,835
5,451
-46,230
-17,096
29,467
-17,433
Change in Cash
-8,068
46,497
4,197
-41,363
23,283
-20,503
13,649
-5,620
-5,337

Novo Nordisk A/S Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
38,130
38,628
38,951
42,138
47,757
55,525
83,683
100,988
102,434
Operating Cash Flow
41,168
44,616
46,782
51,951
55,000
78,887
108,908
120,968
119,102
Investing Cash Flow
-6,571
-12,080
-11,509
-22,436
-31,605
-24,918
-43,892
-128,895
-79,158
Financing Cash Flow
-35,689
-34,521
-35,484
-32,244
-25,493
-51,797
-63,158
8,735
-28,408
Change in Cash
-1,303
-1,529
-218
-3,185
-1,507
1,934
1,739
1,263
10,809

Mutual Funds that own Novo Nordisk A/S Stock

Check out the Mutual Funds with significant holdings in Novo Nordisk A/S.

Global Institutional Holdings in Novo Nordisk A/S

Funds
Holdings
Ameriprise Financial Inc
0.04%
Fisher Asset Management, LLC
0.2%
Northern Trust Corp
0.1%
Loomis, Sayles & Company LP
0.39%
Morgan Stanley - Brokerage Accounts
0.29%
See all

Novo Nordisk A/S News & Key Events

  • img

    Today's Timeline - 12 May

    Tue, 03:55 PM

    -

    Novo Nordisk presents data showing Wegovy's effectiveness in weight loss and health benefits for women across menopause stages.

    Tue, 07:30 PM

    -

    Novo Nordisk highlights higher dose Wegovy's potential to compete with Eli Lilly's Zepbound, showing significant weight loss in trials.

    Tue, 10:52 PM

    -

    Novo Nordisk reports strong weight loss results from Wegovy, with participants losing up to 27.7% of body weight in trials.

Insights on Novo Nordisk A/S

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Novo Nordisk A/S has shown strong profit performance over the last three quarters, with net profits increasing from $20.00 billion to $48.55 billion. This represents an average quarterly growth rate of 35.1%, indicating a consistent upward trend in profitability.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Novo Nordisk A/S has shown strong revenue growth over the last three quarters, increasing from $74.97 billion to $96.82 billion. This represents an average increase of 11.8% in revenue each quarter.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, NVO stock has moved up by 23.7%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, ASTRAZENECA PLC has given 172.5% return, outperforming this stock by 200.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, ASTRAZENECA PLC has given 146.9% return, outperforming this stock by 192.0%

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
OrganisationNovo Nordisk A/S
HeadquartersNovo Alle 1, Bagsvaerd, Denmark, 2880
IndustryDrug Manufacturers - General
CEOMr. Maziar Mike Doustdar B.A.
E-voting on sharesClick here to vote

Key Management of Novo Nordisk A/S

Name

Title

Mr. Karsten Munk Knudsen

Executive VP, CFO & Member of the Management Board

Mr. Maziar Mike Doustdar B.A.

President, CEO & Member of the Management Board

Dr. Martin Holst Lange

EVP of R&D, Chief Scientific Officer and Member of the Management Board

Mr. Emil Kongshoej Larsen

EVP of International Operations & Member of Management Board

Ms. Elin Jager

SVP, Chief of Staff to CEO, Corporate Strategy & Sustainability and Member of Management Board

Ms. Tania Sabroe

EVP of People, Organisation and Corporate Affairs & Member of Management Board

Ms. Thilde Hummel Bogebjerg

Executive VP of Enterprise IT & Quality and Member of Management Board

Mr. John F. Kuckelman

SVP, Group General Counsel, Global Legal, IP & Security and Member of Management Board

Mr. Jamey Millar

Executive VP of US Operations & Member of Management Board

Ms. Hong Chow

Executive VP of Product & Portfolio Strategy and Member of Management Board

FAQs

What is Novo Nordisk A/S share price today?

Novo Nordisk A/S share price today is $46.91 as on . Novo Nordisk A/S share today touched a day high of $47.21 and a low of $46.65.

What is the 52 week high and 52 week low for Novo Nordisk A/S share?

Novo Nordisk A/S share touched a 52 week high of $81.44 on and a 52 week low of $35.12 on . Novo Nordisk A/S stock price today i.e. is trending at $46.91,which is 42.40% down from its 52 week high and 33.57% up from its 52 week low.

What is Novo Nordisk A/S's market capitalisation today?

Novo Nordisk A/S market capitalisation is $0.21T as on .

How to invest in Novo Nordisk A/S Stock (NVO) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Novo Nordisk A/S on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Novo Nordisk A/S Shares that will get you 0.0320 shares as per Novo Nordisk A/S share price of $46.91 per share as on May 13, 2026 at 10:38 pm IST.

What is the minimum amount required to buy Novo Nordisk A/S Stock (NVO) from India?

Indian investors can start investing in Novo Nordisk A/S (NVO) shares with as little as ₹95.705 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹957.05 in Novo Nordisk A/S stock (as per the Rupee-Dollar exchange rate as on ). Based on Novo Nordisk A/S share’s latest price of $46.91 as on May 13, 2026 at 10:38 pm IST, you will get 0.2132 shares of Novo Nordisk A/S. Learn more about fractional shares .

What are the returns that Novo Nordisk A/S has given to Indian investors in the last 5 years?

Novo Nordisk A/S stock has given 19.15% share price returns and 29.72% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?